Related Experiment Video
Updated: Jul 15, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
[Clinical benefits of anti-human IL-6 receptor antibody therapy]
1Osaka University, Graduate School of Frontier Biosciences, Laboratory of Immune Regulation.
Abstract:
Interleukin-6 (IL-6) plays pathological roles in promoting autoimmune reactions and chronic inflammation as well as destruction of bone and cartilage in rheumatoid arthritis (RA). Humanized anti-human IL-6 receptor antibody, tocilizumab, specifically recognizes human IL-6 receptor and inhibits IL-6 actions. Tocilizumab has been shown to ameliorate the disease activity of RA in the clinical trials. Tocilizuamb can be a new therapy based on the pathology of RA.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...